Engineering an alkaline-stable protein A through rational design strategies., PMID:40367905
Development of a fully automated latex-enhanced immunoturbidimetric method for quantitative serum Lp(a) measurement., PMID:40045089
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects., PMID:39928714
The path of GPR87: from a P2Y-like receptor to its role in cancer progression., PMID:39641798
The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report., PMID:39342791
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention., PMID:38970537
Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells., PMID:38837511
Targeting AQP9 enhanced the anti-TNF therapy response in Crohn's disease by inhibiting LPA-hippo pathway., PMID:38583685
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better., PMID:38576462
Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus., PMID:38436267
The impacts of biologic treatment on metabolic profiling in psoriasis., PMID:38284208
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models., PMID:37550785
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention., PMID:37486464
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)., PMID:37111334
Lysophospholipids and their producing enzymes: Their pathological roles and potential as pathological biomarkers., PMID:37061204
Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs., PMID:36806315
The prognostic activity of acylglycerol kinase immunohistochemical expression in colon adenocarcinoma patients., PMID:38572459
Decrease in serum levels of autotaxin in COVID-19 patients., PMID:36369824
Long-Term Blockade of Nociceptive Nav1.7 Channels Is Analgesic in Rat Models of Knee Arthritis., PMID:36358921
New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention., PMID:36213094
Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis., PMID:35931383
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall., PMID:35806908
Pain-like behavior in the collagen antibody-induced arthritis model is regulated by lysophosphatidic acid and activation of satellite glia cells., PMID:35026421
Aberrant ENPP2 expression promotes tumor progression in multiple myeloma., PMID:34847837
Generation of an Lpar1-EGFP Fusion Knock-in Transgenic Mouse Line., PMID:34652685
Working towards full eradication of lipid-driven cardiovascular risk?, PMID:34279797
Gintonin influences the morphology and motility of adult brain neurons via LPA receptors., PMID:34025133
Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding., PMID:33853612
Effects of topical TGF-β1, TGF-β2, ATX, and LPA on IOP elevation and regulation of the conventional aqueous humor outflow pathway., PMID:33633440
Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1., PMID:33584637
Antibodies Against Lysophosphatidic Acid Protect Against Blast-Induced Ocular Injuries., PMID:33384658
New Trends in Dyslipidemia Treatment., PMID:33177309
Antigenic and Substrate Preference Differences between Scorpion and Spider Dermonecrotic Toxins, a Comparative Investigation., PMID:33019554
Lysophosphatidic acid induces tumor necrosis factor-alpha to regulate a pro-inflammatory cytokine network in ovarian cancer., PMID:32851734
Differential anatomical and cellular expression of lysophosphatidic acid receptor 1 in adult mouse brain., PMID:32718668
Biotechnology Approaches for the Treatment of Dyslipidemia., PMID:32519066
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality., PMID:32492513
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)., PMID:32393252
Nucleic Acid-Based Therapies for Atherosclerosis., PMID:32034521
Ectonucleotide pyrophosphatase 2 (ENPP2) plays a crucial role in myogenic differentiation through the regulation by WNT/β-Catenin signaling., PMID:31805399
Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review., PMID:31504506
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice., PMID:31350625
The Future of Lipid-lowering Therapy., PMID:31340607
Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes., PMID:31147448
LPA1 , LPA2 , LPA4 , and LPA6 receptor expression during mouse brain development., PMID:30847983
Molecular mechanism of lysophosphatidic acid-induced hypertensive response., PMID:30804442
Lipid-Lowering Agents., PMID:30702996
Moving Targets: Recent Advances in Lipid-Lowering Therapies., PMID:30676072
Lysophosphatidic acid triggers cathepsin B-mediated invasiveness of human endometriotic cells., PMID:30591146
For research use only. Not for human or drug use.
